Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Marathon's High-Priced Window May Not Stay Open Long

Feb 13 2017

• By Derrick Gingery

StormuSkyWarningSign_1200x675

Related Content

Priority Review Vouchers Appear To Be Dropping In Price

Jul 27 2016

Handling Drug Price Spikes: A Sad Place To Be

Dec 08 2015

Pharma’s Pricing Debate Splinters As US Political Confrontation Looms

Jan 19 2017

Sarepta Snaps Up Gene Therapy Approaches to DMD

Jan 12 2017

Anthem Denies Coverage For Eteplirsen, Citing Lack Of Clinical Efficacy

Oct 07 2016

Drug Pricing Bill May Make Six-Month ANDA Review Slower Than Eight-Month Review

Feb 03 2017

Marathon Gets Long-Known Duchenne Treatment On-Label, But Will Payers Respond?

Feb 10 2017

Related Companies

Marathon Pharmaceuticals LLC

Sarepta Therapeutics, Inc.

Anthem Inc.

Bausch Health Companies Inc.

Vyera Pharmaceuticals, LLC

Viatris Inc.

Reveragen BioPharma, Inc.

Actelion Pharmaceuticals Ltd.

Additional Topics

Approvals Launches Regulation Commercial Rare Diseases BioPharmaceutical Neurology

More from New Products

More from Scrip

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window